Last reviewed · How we verify
Ceftriaxone 1000 MG
At a glance
| Generic name | Ceftriaxone 1000 MG |
|---|---|
| Sponsor | Pomeranian Medical University Szczecin |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Enhanced Molecular Microbiological Surveillance Versus Ceftriaxone Prophylaxis in Hematopoietic Cell Transplant Patients (NA)
- A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea (PHASE3)
- Clearance of Asymptomatic Pharyngeal Carriage of Neisseria Gonorrhoeae With or Without Ceftriaxone Treatment: Randomized Non-inferiority Study (PHASE3)
- Comparison of Efficacy of Two Combination Regimens for the Neisseria Gonorrhoeae and Chlamydia Coinfection (PHASE2)
- New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea (PHASE3)
- Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceftriaxone 1000 MG CI brief — competitive landscape report
- Ceftriaxone 1000 MG updates RSS · CI watch RSS
- Pomeranian Medical University Szczecin portfolio CI